c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
2c
67
1d
2 29
1d
25
Xiao Wang, PhD
88
67
Research Assistant Professor of Medicine (Cardiovascular Medicine)
7
5f
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
46
4
3
3
3
2
4
b
1f
46
3400 Civic Center Blvd.
46 RM 11-172 TRC, Cardiology, Bldg 421
Philadelphia, PA 19104
26
46 RM 11-172 TRC, Cardiology, Bldg 421
Philadelphia, PA 19104
35
99
Email:
xiao8@pennmedicine.upenn.edu
12
xiao8@pennmedicine.upenn.edu
13
Education:
21 7 BS 17 (Bioscience) c
45 College of Life Science, Zhejiang University, 2007.
21 8 PhD 2f (Molecular Biology and Biochemistry) c
58 Institute for Nutritional Sciences, Chinese Academy of Sciences, 2013.
c
3
3
3
3
92
Permanent link21 7 BS 17 (Bioscience) c
45 College of Life Science, Zhejiang University, 2007.
21 8 PhD 2f (Molecular Biology and Biochemistry) c
58 Institute for Nutritional Sciences, Chinese Academy of Sciences, 2013.
c
2 29
21
1e
1d
24
2b
29
27
23
14e Quigley A, Jindal I, Campion T, Rutherford D, Han Y, Quigley W, Qu P, Musunuru K, Ahrens-Nicklas R, Hong X, Wang X.: Base editing strategies for in vivo correction of two highly recurrent phenylketonuria variants. Mol Ther Nucleic Acids 36(4): 102770, Nov 2025.
235 Madelynn N. Whittaker, Lauren C. Testa, Aidan Quigley, Dominique L. Brooks, Sarah A. Grandinette, Hooda Said, Garima Dwivedi, Ishaan Jindal, Daphne Volpp, Julia L. Hacker, Ping Qu, Josh Zhiyong Wang, Michael A. Levine, Rebecca C. Ahrens-Nicklas, Qiaoli Li, Kiran Musunuru, Mohamad-Gabriel Alameh, William H. Peranteau1 & Xiao Wang: Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs. Nature Biomedical Engineering 248(2): 817-834, Oct 2025.
2bb Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC.: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392(22): 2235–2247, May 2025.
176 Choe D, Burke M, Brandimarto JA, Marti-Pamies I, Yob J, Yang Y, Morley MP, Drivas TG, Day S, Levin M, Damrauer S, Wang X*, Cappola TP*.: Sex-Specific Effects of MTSS1 Downregulation on Dilated Cardiomyopathy. Circulation 150(20): 1648-1651, Nov 2024 Notes: (*These authors jointly directed this work).
13b Brooks DL, Whittaker MN, Said H, Dwivedi G, Qu P, Musunuru K, Ahrens-Nicklas RC, Alameh MG, Wang X.: A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. HGG Adv 5(1): 100253, Jan 2024.
13a Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X.: Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am J Hum Genet 110(12): 2003-2014, Dec 2023.
14b Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, Yang Y, Alameh MG, Musunuru K, Wang X.: Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes. Arterioscler Thromb Vasc Biol 43(10): 2075–2077, Oct 2023.
12f Brooks DL, Carrasco MJ, Qu P, Peranteau WH, Ahrens-Nicklas RC, Musunuru K, Alameh MG, Wang X.: Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing. Nat Commun 10(14): 3451, Jun 2023.
15f Davis JR, Wang X, Witte IP, Huang TP, Levy JM, Raguram A, Banskota S, Seidah NG, Musunuru K, Liu DR.: Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng 6(11): 1272-1283, Nov 2022.
2c
7
1d
1f
Selected Publications
155 Testa LC, Obiri-Yeboah D, Said H, Qu P, Levine MA, Alameh MG, Musunuru K, Li Q, Wang X.: Liver-directed base editing of ABCC6 prevents ectopic calcification in a variant-humanized mouse model of pseudoxanthoma elasticum. Mol Ther Nucleic Acids 36(4): 102769, Nov 2025.14e Quigley A, Jindal I, Campion T, Rutherford D, Han Y, Quigley W, Qu P, Musunuru K, Ahrens-Nicklas R, Hong X, Wang X.: Base editing strategies for in vivo correction of two highly recurrent phenylketonuria variants. Mol Ther Nucleic Acids 36(4): 102770, Nov 2025.
235 Madelynn N. Whittaker, Lauren C. Testa, Aidan Quigley, Dominique L. Brooks, Sarah A. Grandinette, Hooda Said, Garima Dwivedi, Ishaan Jindal, Daphne Volpp, Julia L. Hacker, Ping Qu, Josh Zhiyong Wang, Michael A. Levine, Rebecca C. Ahrens-Nicklas, Qiaoli Li, Kiran Musunuru, Mohamad-Gabriel Alameh, William H. Peranteau1 & Xiao Wang: Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs. Nature Biomedical Engineering 248(2): 817-834, Oct 2025.
2bb Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC.: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392(22): 2235–2247, May 2025.
176 Choe D, Burke M, Brandimarto JA, Marti-Pamies I, Yob J, Yang Y, Morley MP, Drivas TG, Day S, Levin M, Damrauer S, Wang X*, Cappola TP*.: Sex-Specific Effects of MTSS1 Downregulation on Dilated Cardiomyopathy. Circulation 150(20): 1648-1651, Nov 2024 Notes: (*These authors jointly directed this work).
13b Brooks DL, Whittaker MN, Said H, Dwivedi G, Qu P, Musunuru K, Ahrens-Nicklas RC, Alameh MG, Wang X.: A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. HGG Adv 5(1): 100253, Jan 2024.
13a Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X.: Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am J Hum Genet 110(12): 2003-2014, Dec 2023.
14b Whittaker MN, Testa LC, Quigley A, Jindal I, Cortez-Alvarado SV, Qu P, Yang Y, Alameh MG, Musunuru K, Wang X.: Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes. Arterioscler Thromb Vasc Biol 43(10): 2075–2077, Oct 2023.
12f Brooks DL, Carrasco MJ, Qu P, Peranteau WH, Ahrens-Nicklas RC, Musunuru K, Alameh MG, Wang X.: Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing. Nat Commun 10(14): 3451, Jun 2023.
15f Davis JR, Wang X, Witte IP, Huang TP, Levy JM, Raguram A, Banskota S, Seidah NG, Musunuru K, Liu DR.: Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat Biomed Eng 6(11): 1272-1283, Nov 2022.
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10